TAD regimen with melphalan to treat 18 cases of multiple myeloma

VernacularTitle:TAD方案加美法仑治疗多发性骨髓瘤18例
Author: Limei CHEN ; Chaomin LI ; Huaiyu WANG ; Jionhong GUAN ; Xiaoli MA
Publication Type:Journal Article
Keywords: Multiple myeloma; Drug therapy,combination
From: Journal of Leukemia & Lymphoma 2008;17(5):351-352,355
CountryChina
Language:Chinese
Abstract: Objective To observe the clinical results of combination therapy for multiple myeloma by arsenic trioxide,melphalan,vitamin C and dexamethasone.Methods 18 cases with multiple myeloma,12 males and 6 females were given the treatment including arsenic trioxide,melphalan,vitamin C and dexamethasone combination therapy;the dosage of arsenic trioxide 10 mg,d1～5,d8～12;vitamin C 1.0 g,d1～5,d8～12;dexamethasone 20 mg,d1～4,d8～11;melphalan 2 mg,tid,d1～12.Complete response(CR),partial response(PR),minimal response(MR),no ehange(NC)were observed.Results The CR werel6.7%(3/18),PR were 77.7%(14/t8),MR were 5.6%(1/18).Conclusion Combinational arsenic trioxide,melphalan,vitamin C and dexamethasone is an effective therapy with less side effects,which can be considered for treating the initial or relapsed or refractory MM.